Sevan Multi-Site Solutions Celebrates 10 Years of Zero Worksite Accidents
3.3.2021 17:00:00 EET | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan) — a global leader in innovative design, program management, construction services and data analytics — has had zero accidents on worksites in 10 years.
Sevan has displayed an exemplary safety record since the company’s inception in 2011. In the past decade, Sevan has logged close to 4 million labor hours with no worksite accidents.
“This milestone is an honor because it’s much more than a number,” John Garcia, Vice President of Safety said. “This statistic means that everyone who spent a day working at one of Sevan’s sites made it home that night to be with their family.”
Sevan’s rigorous safety protocols begin with an extensive new hire orientation followed by field audits and required safety trainings throughout the year. Sevan has led many safety programs for key clients and has a robust Safety Committee comprised of leaders at all levels to provide a broad perspective on safety throughout the company and the world.
“One of our values at Sevan is excellence, and our safety track record demonstrates our commitment to ensuring excellence for our people, clients and partners,” President and CEO Jim Evans said. “When we prioritize safety and promote good work habits, we ensure not only great results, but also the well-being of our team members.”
In 2020, Sevan received their second consecutive ABC STEP Platinum Award, which signifies a high-level of achievement in safety procedures. In September of 2020, Sevan celebrated safety by hosting the Safety Excellence Awards dinner, which honored everyone in Sevan’s network and recognized individuals who go above and beyond. Sevan has received safety awards from numerous clients, and internally has an Excellence in Safety recognition program for team members who go above and beyond to set a high bar for safety.
In 2020, Sevan was recognized as an Employee-Rated Great Place to Work® for the 7th consecutive year and ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. Also, in 2020, Sevan ranked No. 16 on Engineering News-Record (ENR)’s Top 50 Program Management Firms and No. 34 on ENR’s Top 100 Construction Management-for-Fee Firms. Visit our website to learn more about Sevan, our award rankings and acquisitions.
Sevan is a construction and project management firm that leverages innovative technology to deliver excellence to clients. Sevan is headquartered near Chicago in Downers Grove, Illinois with 400+ employees and has an international office in London.
About Sevan
The vision of Sevan Multi-Site Solutions is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands, including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Chipotle, DaVita, HCA Healthcare, Hallmark, HEB, Jiffy Lube, Kroger, Marathon, McDonald’s, Office Depot, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart and Zaxby’s. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes construction of new builds, rebuilds, remodels and renovations. Sevan has licensed architects in 49 states as well as D.C., Canadian provinces, Guam and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 21,000 retail stores and 14,000 restaurants and completed more than 28,000 surveys. Sevan Elevate, a program that reinforces and continuously improves safety and sustainability across the company, is designed to impactfully deliver excellence to Sevan’s people and clients. To read more about Sevan, visit www.sevansolutions.com.
For more information, please contact Hafsa Mahmood by calling +1 312.285.0590 or via e-mail at hafsa.mahmood@sevansolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005341/en/
Contact information
Hafsa Mahmood
Director, Communications and DE&I March 3, 2021
Phone: 312.285.0590
Email:
hafsa.mahmood@sevansolutions.com
Website:
www.sevansolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom